Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Coronary Artery Disease (CAD) Clinical Trial

Official title:

A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00826280
• Other study ID #: 3606-CL-3002
• Status: Completed
• Phase: Phase 3
• First received: January 21, 2009
• Last updated: November 20, 2017
• Start date: March 24, 2009
• Est. completion date: July 15, 2010

Study information

• Verified date: November 2017
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI

Description:

All subjects will undergo rest and stress scans. Those subjects who qualify by demonstrating at least 1 reversible defect, will undergo a third scan. All stress scans will involve the injection of regadenoson as the pharmacologic stress agent. Prior to the third scan, the subject will be administered blinded capsules of placebo or caffeine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 347
• Est. completion date: July 15, 2010
• Est. primary completion date: July 15, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject must have undergone a previous diagnostic study [e.g., SPECT, echocardiography, magnetic resonance imaging (MRI), etc.] for a clinical indication demonstrating evidence of reversible defects in = 1 vascular segment, have had other stress testing within the past 3 months, or the subject's history suggests at least a 50% likelihood of CAD

• If the previous diagnostic study shows only 1 reversible defect and it is in segment 17, another reversible defect will need to be present

• Subject with CAD must have an intermediate/low-risk for immediate intervention

• Subject must ingest caffeinated food or beverages regularly (at least the equivalent of one cup of caffeinated coffee daily)

• Subject must agree to not ingest any caffeine or other foods containing methylxanthine at least 24 hours prior to each study visit

• Subject must agree to abstain from eating solid food or drinking liquids other than water for at least 30 minutes prior to each study visit and 30 minutes following each study visit

Exclusion Criteria:

• Subject with documented myocardial infarction (MI) = 30 days prior to enrollment

• Subject with history of percutaneous coronary intervention (PCI) = 4 weeks prior to enrollment

• Subject with history of coronary artery bypass graft (CABG) = 8 weeks prior to enrollment

• Subject has prior history of heart transplantation

• Subject has unstable angina, known severe left main coronary artery stenosis, severe heart failure, uncontrolled arrhythmias, symptomatic hypotension or severe hypertension (systolic blood pressure < 90 or > 180 mmHg, respectively), or > 1st degree atrioventricular block in the absence of a functioning pacemaker

• Subject requires emergent cardiac medical intervention or catheterization

• Subject has a history of smoking, regardless of frequency, tobacco type or method of intake, or using any smoking cessation products, including but not limited to the nicotine patch or nicotine gum, within 3 months prior to first dose of regadenoson

• Subject is currently undergoing treatment with theophylline, or theophylline containing medications within 7 days prior to randomization (Day 3)

• Subject has a history of known or suspected bronchoconstrictive or bronchospastic lung disease [e.g., asthma, wheezing, chronic obstructive pulmonary disease (COPD), etc.]

• Subject has a history of diabetes associated with gastric disorders and/or emptying

• Subject has end stage renal disease (ESRD) with a GFR< 15mL/min or currently undergoing dialysis for ESRD

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Artery Disease (CAD)
• Coronary Disease
• Myocardial Ischemia

Intervention

Drug:
• regadenoson
IV
• overencapsulated caffeine
oral

Radiation:
• technetium
IV

Drug:
• placebo
oral

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Number of Reversible Defects	Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was = 2.; Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).	Day 3 and Day 5
Secondary	Change in Summed Difference Score (SDS) Across All 17 Segments	The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).; Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).; The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).	Day 3 and Day 5
Secondary	Change in Number of Reversible Defects Assessed by Computerized Quantitation	Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was = 2.; Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).	Day 3 and Day 5
Secondary	Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation	The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).; Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).; The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).	Day 3 and Day 5
Secondary	Change From Baseline in Heart Rate	Baseline is the last non-missing measurement on or before first dose of regadenoson; Change is calculated as the time point minus baseline.	Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)
Secondary	Change From Baseline in Systolic Blood Pressure	Baseline is the last non-missing measurement on or before first dose of regadenoson.; Change is calculated as the time point minus baseline.	Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)
Secondary	Change From Baseline in Diastolic Blood Pressure	Baseline is the last non-missing measurement on or before first dose of regadenoson.; Change is calculated as the time point minus baseline.	Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)

External Links

•   Link to results on Astellas Clinical Study Results website